Publicacións en colaboración con investigadores/as de Hospital Álvaro Cunqueiro (34)

2024

  1. Consecutive or selectively included high bleeding risk patients in the MASTER DAPT screening log and trial

    European Journal of Internal Medicine, Vol. 126, pp. 89-94

  2. Mitral Valve Transcatheter Edge-to-Edge Repair: 1-Year Outcomes From the MiCLASP Study

    JACC: Cardiovascular Interventions, Vol. 17, Núm. 7, pp. 890-903

2023

  1. Impact of Age at the Time of the First ST-Elevation Myocardial Infarction on 10-Year Outcomes (from the EXAMINATION-EXTEND Trial)

    American Journal of Cardiology, Vol. 190, pp. 32-40

  2. Relationship between stent length and very long-term target lesion failure following percutaneous coronary intervention for ST-elevation myocardial infarction in the drug-eluting stents era: insights from the EXAMINATION-EXTEND study

    American Heart Journal, Vol. 264, pp. 72-82

2022

  1. A Score to Assess Mortality After Percutaneous Mitral Valve Repair

    Journal of the American College of Cardiology, Vol. 79, Núm. 6, pp. 562-573

  2. Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk

    Journal of the American College of Cardiology, Vol. 80, Núm. 13, pp. 1220-1237

  3. Impact of Diabetes on 10-Year Outcomes Following ST-Segment–Elevation Myocardial Infarction: Insights From the EXAMINATION-EXTEND Trial

    Journal of the American Heart Association, Vol. 11, Núm. 23

  4. Magnesium-based resorbable scaffold vs permanent metallic sirolimus-eluting stent in patients with ST-segment elevation myocardial infarction: 3-year results of the MAGSTEMI randomised controlled trial

    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, Vol. 18, Núm. 5, pp. e389-e396

  5. Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial

    European Journal of Heart Failure, Vol. 24, Núm. 3, pp. 581-588

  6. Sex Differences in 10-Year Outcomes Following STEMI: A Subanalysis From the EXAMINATION-EXTEND Trial

    JACC: Cardiovascular Interventions, Vol. 15, Núm. 19, pp. 1965-1973

2021

  1. 10-Year Follow-Up of Patients With Everolimus-Eluting Versus Bare-Metal Stents After ST-Segment Elevation Myocardial Infarction

    Journal of the American College of Cardiology, Vol. 77, Núm. 9, pp. 1165-1178

  2. Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial

    Circulation, Vol. 144, Núm. 15, pp. 1196-1211

  3. Dual antiplatelet therapy after PCI in patients at high bleeding risk

    New England Journal of Medicine, Vol. 385, Núm. 18, pp. 1643-1655

  4. Impact of coronary lesion complexity in percutaneous coronary intervention: One-year outcomes from the large, multicentre e-Ultimaster registry

    EuroIntervention, Vol. 16, Núm. 7, pp. 603-612

  5. Sex differences in 1-year clinical outcomes after percutaneous coronary intervention with COMBO stents: From the COMBO collaboration

    Catheterization and Cardiovascular Interventions, Vol. 97, Núm. 5, pp. 797-804

2020

  1. 1-Year COMBO stent outcomes stratified by the PARIS bleeding prediction score: From the MASCOT registry

    IJC Heart and Vasculature, Vol. 31

  2. 1-Year Outcomes with COMBO Stents in Small-Vessel Coronary Disease: Subgroup Analysis From the COMBO Collaboration

    Cardiovascular Revascularization Medicine, Vol. 21, Núm. 12, pp. 1542-1547

  3. 1-year results after PCI with the COMBO stent in all-comers in Asia versus Europe: Geographical insights from the COMBO collaboration

    International Journal of Cardiology, Vol. 307, pp. 17-23

  4. Bioresorbable scaffolds versus permanent sirolimus-eluting stents in patients with st-segment elevation myocardial infarction: Vascular healing outcomes from the magstemi trial

    EuroIntervention, Vol. 16, Núm. 11, pp. E913-E921

  5. Comparison of One-Year Outcomes in Patients >75 Versus ≤75 Years With Coronary Artery Disease Treated With COMBO Stents (From The MASCOT Registry)

    American Journal of Cardiology, Vol. 127, pp. 1-8